ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2022
Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Renal outcomes in valve-in-valve transcatheter versus redo surgical aortic valve replacement: A systematic review and meta-analysis.Journal of cardiac surgery · 2022Pooled it
- Prognostic implications and predictive factors of subclinical leaflet thrombosis following valve-in-valve transcatheter aortic valve implantation.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Trial
- Clinical Outcomes of the Allegra Transcatheter System in Bioprosthetic Aortic Valve Failure: A Multicentre Valve-in-Valve Registry.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Valve-in-Valve TAVR Versus Redo Surgery in Women With Degenerated Aortic Bioprosthesis: A Single-Center Experience.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
- Cost-Effectiveness of Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo-Surgical Aortic Valve Replacement for Degenerated Bioprosthetic Aortic Valve.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- A single-center study on prosthesis selection strategy in aortic valve replacement for patients aged 50-65 years.Journal of thoracic disease · 2026Article
- Comparative analysis of postoperative outcomes and utilization trends for valve-in-valve transcatheter aortic valve implantation versus reoperative surgical aortic valve replacement.Journal of cardiothoracic surgery · 2026Article
- Comparing short- and long-term outcomes of transcatheter valve-in-valve versus redo surgical aortic valve replacement: a literature review.Journal of cardiothoracic surgery · 2026Review
- National Trends and In-Hospital Outcomes of Valve-in-Valve Transcatheter Aortic Valve Replacement With Cerebral Embolic Protection.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Successful Valve-in-Valve-in-Valve Procedure in a Patient With Severe Aortic Prosthesis Dysfunction: A Case Report.Cureus · 2026Article
- [The TAVI heart team].Herz · 2025Article
- Comparison of Latest Generation Intra- and Supra-Annular Self-Expanding Transcatheter Heart Valves for Aortic Valve-in-Valve Procedures.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- Individualized Selection of Valve Intervention Strategies in Aortic Disease Is Key for Better Outcomes.Journal of personalized medicine · 2025Review
- Live Hemodynamics-Assisted Simultaneous Aortic and Mitral Valve-in-Valve Replacement.JACC. Case reports · 2025Article
- The International TrifectaCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- Virtual reality for pre-procedural planning of valve-in-valve transcatheter aortic valve implantation.European heart journal. Digital health · 2025Article
- Management of bioprosthetic valve failure at 10 years after TAV-in-SAV.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Acurate Neo2 for valve-in-valve treatment of degenerated 3F Enable sutureless bioprosthetic valve in nonagenarian patient: a case report.European heart journal. Case reports · 2025Article
- A "Watchful Surgery" Approach: Timing and Valve Choice for Mildly Symptomatic Mitral and Aortic Valve Disease.Journal of surgery and research · 2025Article
- Transcatheter Aortic Valve Implantation Indications and Patient Selection.Interventional cardiology (London, England) · 2025Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data are available regarding clinical outcomes of valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) following the United States Food and Drug Administration approval of ViV TAVI in 2015.
aimsThe aim of this study was to evaluate in-hospital, 30-day, and 6-month outcomes of ViV TAVI versus repeat surgical aortic valve replacement (SAVR) in patients with a failed aortic bioprosthetic valve.
methodsThis retrospective cohort study identified patients who underwent ViV TAVI or repeat SAVR utilising the Nationwide Readmission Database from 2016 to 2018. Primary outcomes were all-cause readmission (at 30 days and 6 months) and in-hospital death. Secondary outcomes were in-hospital stroke, pacemaker implantation, 30-day/6-month major adverse cardiac events (MACE), and mortality during readmission. Propensity score-matching (inverse probability of treatment weighting) analyses were implemented.
resultsOut of 6,769 procedures performed, 3,724 (55%) patients underwent ViV TAVI, and 3,045 (45%) underwent repeat SAVR. ViV TAVI was associated with lower in-hospital all-cause mortality (odds ratio [OR] 0.42, 95% confidence interval [CI]: 0.20-0.90, p=0.026) and a higher rate of 30-day (hazard ratio [HR] 1.46, 95% CI: 1.13-1.90, p=0.004) and 6-month all-cause readmission (HR 1.54, 95% CI: 1.14-2.10, p=0.006) compared with repeat SAVR. All secondary outcomes were comparable between the two groups.
conclusionsViV TAVI was associated with lower in-hospital mortality but higher 30-day and 6-month all-cause readmission. However, there was no difference in risk of in-hospital stroke, post-procedure pacemaker implantation, MACE, and mortality during 30-day and 6-month readmission compared with repeat SAVR, suggesting that ViV TAVI can be performed safely in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.